Diagnosis and Treatment Diagnosis and Treatment of Dyslipidemia of Dyslipidemia New guidelines are based on the New guidelines are based on the “Adult “Adult Treatment Plan III (ATP III)” Treatment Plan III (ATP III)” 2004 2004 Focus = multiple risk factor assessment Focus = multiple risk factor assessment to determine those individuals at highest to determine those individuals at highest absolute Coronary Heart Disease (CHD) absolute Coronary Heart Disease (CHD) risk risk Diabetes is identified as being a Diabetes is identified as being a CHD risk CHD risk equivalent equivalent - in other words, a person with - in other words, a person with Diabetes is considered at the Diabetes is considered at the same risk same risk of CHD of CHD as a person with a previous hx of as a person with a previous hx of CHD CHD
11
Embed
Diagnosis and Treatment of Dyslipidemia New guidelines are based on the “Adult Treatment Plan III (ATP III)” 2004 Focus = multiple risk factor assessment.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Diagnosis and Treatment Diagnosis and Treatment of Dyslipidemiaof Dyslipidemia
New guidelines are based on the New guidelines are based on the “Adult “Adult Treatment Plan III (ATP III)”Treatment Plan III (ATP III)” 2004 2004
Focus = multiple risk factor assessment to Focus = multiple risk factor assessment to determine those individuals at highest absolute determine those individuals at highest absolute Coronary Heart Disease (CHD) riskCoronary Heart Disease (CHD) risk
Diabetes is identified as being a Diabetes is identified as being a CHD risk CHD risk equivalentequivalent - in other words, a person with - in other words, a person with Diabetes is considered at the Diabetes is considered at the same risk of same risk of CHDCHD as a person with a previous hx of CHD as a person with a previous hx of CHD
Assessing CHD RiskAssessing CHD Risk
Framingham Risk ScoreFramingham Risk Score - Projects - Projects potential for 10 year absolute CHD Risk potential for 10 year absolute CHD Risk (ranges from < 10% to > 20%) (ranges from < 10% to > 20%)
Use in patients Use in patients withoutwithout CHD or CHD CHD or CHD Risk EquivalentsRisk Equivalents
Lipid EvaluationLipid Evaluation
Done after a Done after a 9 – 12 hour9 – 12 hour fast to ensure fast to ensure an adequate evaluation of all an adequate evaluation of all components of a lipid profilecomponents of a lipid profile
If Triglycerides are extremely elevated, If Triglycerides are extremely elevated, calculation of the LDL can be difficult calculation of the LDL can be difficult
Non-fasting samples should not be used Non-fasting samples should not be used for diagnosis for diagnosis
Medications for Medications for Treatment of Treatment of DyslipidemiaDyslipidemia
New Recommendations in TherapeuticsNew Recommendations in Therapeutics - - Combination therapyCombination therapy is recommended is recommended
for selected high risk patientsfor selected high risk patients
- Despite success of the statins as a- Despite success of the statins as a group, coronary event rates remain highgroup, coronary event rates remain high
- Combination therapy may be as efficacious - Combination therapy may be as efficacious as single therapy with less side effects as single therapy with less side effects
- Side effects and toxicity of statins increase- Side effects and toxicity of statins increase with each dosage increment with each dosage increment
Types of MedicationsTypes of Medications Drugs that Affect Hepatic Lipoprotein Drugs that Affect Hepatic Lipoprotein